STOCK TITAN

Immutep: 81.1% 1-year disease-free survival in sarcoma

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Immutep reported new survival data from the EFTISARC-NEO Phase II trial, which evaluates eftilagimod alfa with pembrolizumab and radiotherapy before surgery for high-risk, resectable soft tissue sarcoma. Forty patients enrolled; 38 underwent surgery and were included in the survival evaluation. 12-month disease-free survival was 81.1%; the 18-month estimate was also 81.1% but remains immature, with follow-up ongoing. Eight of the 38 evaluated patients had recurrence by April 30, 2026.

At 12 months, local recurrence-free survival was 94.1% and distant metastasis-free survival was 86.2%; median follow-up was 19.1 months. Exploratory analyses reported 95.0% 12-month disease-free survival for patients with post-treatment tumour-infiltrating lymphocyte levels above 310 cells/mm², versus 64.9% at lower levels; the results may indicate an association. Immutep is preparing a registration-directed trial, targeting initiation in H2 CY2027 subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources.

Patients enrolled 40 patients EFTISARC-NEO Phase II trial
Patients included in survival evaluation 38 patients Patients who underwent surgery
12-month disease-free survival 81.1% Latest analysis; mature
18-month disease-free survival 81.1% Kaplan-Meier estimate; immature
Recurrences 8 patients Among 38 evaluated patients at the April 30, 2026 data cut-off
12-month local recurrence-free survival 94.1% Latest analysis
12-month distant metastasis-free survival 86.2% Latest analysis
Median follow-up 19.1 months EFTISARC-NEO survival analysis
disease-free survival (DFS) medical
"disease-free survival (DFS) of 81.1% at 12 months"
Disease-free survival measures the length of time after treatment during which a patient shows no signs of the disease returning. Think of it like the period a repaired car runs without any new problems; longer disease-free survival suggests a treatment is working well, which matters to investors because it can influence regulatory approval, clinical adoption, and the potential future sales and valuation of companies developing the therapy.
Kaplan-Meier estimate medical
"current Kaplan-Meier estimate at 18 months"
A Kaplan-Meier estimate is a statistical curve that shows how the chance of avoiding a particular event (like disease progression, treatment failure, or death) changes over time among a group of people in a clinical study. Think of it like a chart tracking how many lightbulbs remain working as hours pass; for investors it matters because it summarizes a drug or treatment’s durability and timing of benefits, which can influence regulatory decisions, market expectations, and valuation.
tumour-infiltrating lymphocytes (TILs) medical
"higher levels of tumour-infiltrating lymphocytes (TILs)"
tertiary lymphoid structures (TLS) medical
"The presence of tertiary lymphoid structures (TLS)"
neoadjuvant treatment medical
"as neoadjuvant treatment for patients with resectable soft tissue sarcoma"
Neoadjuvant treatment is medicine given before the main therapy—usually surgery—to shrink a tumor or slow disease so the primary treatment has a better chance of working. Think of it as trimming branches before cutting down a tree: it can make the main procedure easier, less risky, or more successful. For investors, neoadjuvant success can speed regulatory approval, expand a drug’s market by showing clear clinical benefit earlier, and boost commercial prospects.
MHC Class II agonist technical
"proprietary soluble LAG-3 protein and MHC Class II agonist"
A MHC class II agonist is a molecule that binds to and stimulates major histocompatibility complex class II proteins, which present pieces of foreign or internal proteins to helper T cells in the immune system. Think of it as a tool that boosts the ‘display and call-to-action’ function on immune cells so helper T cells recognize and respond to targets; for investors, it signals a specific immune-modulating mechanism relevant to vaccines and certain immunotherapies, with implications for effectiveness and safety.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What disease-free survival did IMMP report from EFTISARC-NEO?

The trial reported 81.1% 12-month disease-free survival; the 18-month Kaplan-Meier estimate was also 81.1% and remains immature. Among the 38 patients who underwent surgery and were evaluated, eight had experienced recurrence by April 30, 2026.

What exploratory biomarker findings did IMMP report?

Post-treatment tumour-infiltrating lymphocyte levels above 310 cells/mm² may be associated with 95.0% 12-month disease-free survival, compared with 64.9% at lower levels. Treatment-related hyalinisation and fibrosis above 52% were reported alongside 93.8% disease-free survival, versus 71.4% at lower levels.

When is IMMP targeting the start of a registration-directed sarcoma trial?

Immutep is targeting initiation in H2 CY2027, subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as November 19, 2026

Commission File Number 001-35428

 

 

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

 

 

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

 

 
 


EXHIBIT INDEX

 

Exhibit

 

Description of Exhibit

99.1

 

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 19, 2026

 

IMMUTEP LIMITED
By:  

/s/ Marc Voigt

Name:   Marc Voigt
Title:   Chief Executive Officer

Exhibit 99.1

 

LOGO

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

 

  •  

Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of 81.1% in patients with resectable soft tissue sarcoma.

 

  •  

Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels.

 

  •  

Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels.

 

  •  

Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy.

SYDNEY, AUSTRALIA – November 19, 2026 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announced new data from the investigator-initiated EFTISARC-NEO Phase II study presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster number P 448).

The study is evaluating Immutep’s eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma. Forty patients were enrolled, and 38 patients underwent surgery and were included in the survival evaluation.

The latest analysis currently shows a disease-free survival (DFS) of 81.1% at 12 months. The current Kaplan-Meier estimate at 18 months is also 81.1%, although this later time point remains immature, and follow-up is ongoing. Among the 38 patients who underwent surgery and were evaluated, eight patients had experienced disease recurrence at the data cut-off (April 30, 2026).

Table 1 – Survival results for soft tissue sarcoma patients from EFTISARC-NEO

 

Outcome

   Latest Analysis  

12-month disease-free survival (mature)

     81.1 % 

18-month disease-free survival (immature)

     81.1 % 

12-month local recurrence-free survival

     94.1 % 

12-month distant metastasis-free survival

     86.2 % 

Median follow-up

     19.1 months  

 

LOGO


LOGO

 

In addition, exploratory analyses showed that higher levels of tumour-infiltrating lymphocytes (TILs) and greater hyalinisation and fibrosis after treatment may be associated with better DFS. In particular, patients with post-treatment TIL levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels. Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels of hyalinisation and fibrosis. The presence of tertiary lymphoid structures (TLS) and baseline expression of PD-L1, LAG-3 and TIGIT did not correlate with survival outcomes.

These survival and exploratory findings build on previously reported EFTISARC-NEO results in which the trial met its primary endpoint with a median tumour hyalinisation/fibrosis of 51.5% following neoadjuvant therapy with efti, pembrolizumab and radiotherapy. The new data are consistent with efti’s mechanism of action, in which activation of antigen-presenting cells drives a stronger anti-tumour T cell response, and suggest that a stronger immune response in the tumour may be associated with improved patient survival outcomes.

Pawel Sobczuk, MD PhD, one of the Principal Investigators of EFTISARC-NEO, said: “These results are highly encouraging for patients with high-risk soft tissue sarcoma, where recurrence remains a major concern despite surgery and radiotherapy. Disease-free survival of approximately 81% maintained through 12 months and on a preliminary basis also at 18 months is an important observation, and the association between a strong immune response in the tumour and better disease-free survival is particularly compelling. Together with the substantial pathological responses previously reported, the findings reinforce the potential of this novel neoadjuvant approach and provide a strong rationale for continued follow-up and further clinical evaluation.”

Marc Voigt, CEO of Immutep, said: “With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture. The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response. We believe these results strengthen the rationale for further potential clinical development in this indication, where patients remain in need of more effective treatment options.”

The poster is available on the Posters & Publications page of Immutep’s website.

Next Steps

Immutep anticipates reporting additional data from EFTISARC-NEO in CY2027.

Subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources, the Company is preparing to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in H2 CY2027.

About EFTISARC-NEO

EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria

 

LOGO


LOGO

 

Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti.

The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).

About Eftilagimod Alfa (efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

 

LOGO


LOGO

 

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.

+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media:

Matthew Beck, astr partners

+1 (917) 415-1750; matthew.beck@astrpartners.com

This announcement was authorised for release by the Board of Immutep Limited.

 

LOGO

Filing Exhibits & Attachments

1 document

Keep reading